SCHEMBL1500702

SCHEMBL1500702

N#Cc1cccc([C@H](c2ccc(Cl)cc2)N2CC(=O)C2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.42
OPRD1 P41143 1/20 0.41
CNR1 P21554 8/20 0.41
CNR2 P34972 5/20 0.40
CYP2D6 P10635 2/20 0.40
CYP19A1 P11511 1/20 0.40
ADRA1A P35348 2/20 0.40
CHRM2 P08172 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
BCL2 P10415 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD1 P21728 1/20 0.40
TBXA2R P21731 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
DRD3 P35462 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KCNH2 Q12809 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1500704 1.00 MGLL (0.42) MGLLOPRD1CNR1CNR2CYP2D6
SCHEMBL1500612 0.81 MGLL (0.43) MGLLOPRD1CNR1CNR2CYP2D6
SCHEMBL1500614 0.81 MGLL (0.43) MGLLOPRD1CNR1CNR2CYP2D6
SCHEMBL1500553 0.80 CYP2D6 (0.53) MGLLOPRD1CYP2D6CYP19A1ADRA1A
Bromide SCHEMBL3300210 0.78 CYP2D6 (0.52) MGLLOPRD1CYP2D6CYP19A1ADRA1A
SCHEMBL3670679 0.77 MGLL (0.43) MGLLCNR1CNR2SLC6A2SLC6A4
SCHEMBL3670680 0.77 MGLL (0.43) MGLLCNR1CNR2SLC6A2SLC6A4
SCHEMBL6011569 0.75 CNR1 (0.43) MGLLCNR1CNR2
SCHEMBL1528945 0.74 CNR1 (0.39) MGLLCNR1CNR2ADRA1ACHRM2
SCHEMBL1528612 0.74 CNR1 (0.44) CNR1CNR2ADRA1AADRA1DADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906652-B2 Heterocycle-substituted 3-alkyl azetidine derivatives MERCK SHARP & DOHME CORP. (US) 2011-03-15 US disclosed
US-20100081642-A1 CB-1 RECEPTOR MODULATOR PHARMACEUTICAL FORMULATIONS MERCK SHARP & DOHME CORP. 2010-04-01 US disclosed
US-20070123505-A1 Heterocycle-substituted 3-alkyl azetidine derivatives MERCK SHARP & DOHME CORP. 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123505-A1 Heterocycle-substituted 3-alkyl azetidine derivatives CNR1, CNR2, FAAH MGLL 444/4885OPRD1 81/4885CNR1 1/4885
US-20100081642-A1 CB-1 RECEPTOR MODULATOR PHARMACEUTICAL FORMULATIONS CNR1, CNR2, GPBAR1 MGLL 625/4885OPRD1 62/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.